Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.41 |
| ▸ | TERT | O14746 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | MME | P08473 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CTSD | P07339 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | NMT2 | O60551 | 1/20 | 0.34 |
| ▸ | NMT1 | P30419 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29369101 | 0.90 | OPRM1 (0.49) | OPRM1OPRD1TERTMMEOPRK1 | |
| SCHEMBL29823325 | 0.88 | ALDH1A1 (0.42) | OPRM1OPRD1TERTCTSD | |
| SCHEMBL30422914 | 0.88 | ITGB3 (0.39) | OPRD1TERTCTSBCTSD | |
| SCHEMBL29349612 | 0.87 | ALDH1A1 (0.42) | OPRD1TERTSMN1; SMN2 | |
| SCHEMBL29351781 | 0.85 | MME (0.47) | OPRM1OPRD1TERTMMEOPRK1 | |
| SCHEMBL29930416 | 0.85 | MME (0.40) | MMESMN1; SMN2 | |
| SCHEMBL31643053 | 0.84 | CTSB (0.46) | OPRM1OPRD1CTSBMMECTSD | |
| SCHEMBL29478036 | 0.84 | NMT1 (0.43) | OPRM1OPRD1CTSBNMT2NMT1 | |
| SCHEMBL7555588 | 0.82 | PTGS1 (0.46) | OPRM1OPRD1TERTMMEOPRK1 | |
| SCHEMBL7555590 | 0.82 | PTGS1 (0.46) | OPRM1OPRD1TERTMMEOPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11999802-B2 | Compositions and methods for selective protein degradation | NOVARTIS AG (CH) | 2024-06-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11999802-B2 | Compositions and methods for selective protein degradation | CRBN, RPS27A, COPB1 | OPRM1 4505/4885OPRD1 4522/4885TERT 2891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.